Sökning: onr:"swepub:oai:lup.lub.lu.se:f1a3da48-8d2a-41f7-8c4c-19f67abba743" >
Octreotide scintigr...
Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
-
- Kalkner, Karl Mikael (författare)
- Karolinska University Hospital
-
- Acosta, Stefan (författare)
- Blekinge Hospital
-
- Thorsson, Ola (författare)
- Lund University,Lunds universitet,Klinisk fysiologi och nuklearmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Physiology and Nuclear Medicine, Malmö,Lund University Research Groups,Skåne University Hospital
-
visa fler...
-
- Frederiksen, Hans (författare)
- Lund University,Lunds universitet,Urologi,Forskargrupper vid Lunds universitet,Urology,Lund University Research Groups,Skåne University Hospital
-
Nilsson, A (författare)
-
- Gustavsson, Bengt (författare)
- Novartis Sverige AB
-
- Elingsbo, Marie (författare)
- Novartis Sverige AB
-
- Stridsberg, M (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Clinical Chemstry
-
- Abrahamsson, Per-Anders (författare)
- Lund University,Lunds universitet,Urologi, Malmö (Abrahamsson),Forskargrupper vid Lunds universitet,Urological research, Malmö,Lund University Research Groups,Skåne University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2005-10-18
- 2006
- Engelska.
-
Ingår i: Prostate Cancer and Prostatic Diseases. - : Springer Science and Business Media LLC. - 1476-5608 .- 1365-7852. ; 9:1, s. 92-98
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://www.nature.c...
-
http://www.ncbi.nlm....
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- In this pilot study, the predictive value of Octreotide scintigraphy (Octreoscan) and/or Chromogranin-A (CgA) was investigated in patients with hormone-refractory prostate cancer treated with Octreotide acetate. In total, 20 patients with progressive disease and bone metastases entered the trial. At baseline Octreoscan, CgA, PSA, alkaline phosphates (ALP) and two self-administered questionnaires (EORTC QLQ C-30 (v3) and brief pain index) were performed and a diary of the pharmaceutical was started. The treatment consisted of Octreotide (Sandostatin LAR) acetate 30 mg intramuscular injection every month. The blood samples and questionnaires were repeated every month until 3 months. Clinical responder was defined as a patient with increased global health score more than 10 units and stable or decreased pain score without an increase in analgesic. In all, 17 patients were treated per protocol, and four were assessed as clinical responders. Six patients developed a reduction in ALP (median -26%, range -5 to -78%). All patients increased in PSA. At baseline, three patients had a negative Octreoscan and the patients with positive lesions, demonstrated uptake of low intensity. At baseline the CgA was elevated above the normal range in 15 of the patients, and during treatment five patients decreased their CgA to the normal range. Neither baseline Octreoscan nor CgA could identify the clinical reponders. A minority of patients improves their health-related quality of life. The decrease and normalization of CgA levels in five patients during therapy indicates therapeutic activity but Octreoscan and CgA could not identify clinical responders.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- somatostatin analog
- prostate cancer
- neuroendocrine differentiation
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas